- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01704989
The Laser in Pseudoexfoliation (LIP) Study (LIP)
A Randomised Controlled Trial to Compare the Clinical Effectiveness of Selective Laser Trabeculoplasty (SLT) Versus Topical Therapy in the Treatment of Pseudoexfoliative Glaucoma
Study Overview
Detailed Description
Objectives:
The primary aim of this study is to compare the effectiveness, in terms of intraocular pressure (IOP) control, of SLT and topical medical therapy in the primary treatment of patients with high IOP secondary to PXF. The secondary aims of the study are:
- To examine the relationship between the degree of angle pigmentation and reduction of IOP
- To examine adverse effects from SLT treatment in patients with PXF
- To compare IOP-lowering effects of SLT in patients with PXF to patients with POAG (in the LiGHT study, see structure below).
Study Population: All new patients with PXF who are naïve to treatment (and willing to participate) will be recruited after their first hospital consultation. Both eyes will be treated but only one eye per patient included in the analysis (eye with the higher presenting IOP).
Structure: The study design mirrors that of National Institute of Health (NIHR-) funded, the laser in glaucoma and ocular hypertension trial (LiGHT) in the UK and is a collaborative study between a Canadian Institute and Moorfields Eye Hospital in London. This is a single-study randomised (unmasked) control trial of a proposed treatment intervention (SLT) versus a standard treatment (topical therapy).
Summary of study design Patients will be randomised to one of 2 trial arms: 'laser-pathway' or 'medicine- pathway'. Following initial treatment, SLT patients will be followed up 1-2 weeks after treatment to check IOP and for potential side effects. The interval of subsequent follow-up visits (between 4 and 12 months) will be governed by the level of IOP in relation to the target IOP and the severity of glaucoma. Visual field testing (SITA standard, 24-2 test pattern) and imaging with the Hedidelberg Retina Tomograph (HRT III) will be performed at each visit. Target IOP will be set using the Canadian Glaucoma Society guidelines depending on the severity of glaucoma and the level of IOP. At subsequent visits, treatment will be escalated if the target IOP is not met or if there is evidence of progression.
Duration of study The study will last 3 years. One year will be allowed for recruitment of all study participants, so that a minimum follow-up of 2 years will be available.
All patients will have a medical history, gonioscopy, central corneal thickness (CCT) measurement, IOP measurement with Goldmann applanation tonometry and dilated fundoscopy at the baseline visit.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- Eye Care Centre, VG Site, QEII
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Evidence of PXF material on the anterior chamber structures by slit lamp biomicroscopy.
- An open drainage angle with no irido-trabecular contact on non-indentation gonioscopy in primary position trabecular meshwork visible over 360 degrees.
- Ocular hypertension or glaucoma deemed to require treatment by the attending clinician.
- A decision to treat has been made by a Consultant Glaucoma Specialist.
- Age over 18 years and able to provide informed consent.
Exclusion Criteria:
- Advanced glaucoma as determined by EMGT criteria 1: visual field loss mean deviation worse than -12 dB in the better or -15 dB in the worse eye.
- Co-existing other secondary glaucoma (e.g. pigment dispersion syndrome, rubeosis etc) or angle closure glaucoma.
- History of retinal ischaemia, macular oedema or diabetic retinopathy.
- Age-related macular degeneration with neovascularisation or geographic atrophy and VA worse than 6/36.
- Any previous intra-ocular surgery, except uncomplicated phacoemulsification at least one year before.* Medically unfit for completion of the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Laser pathway
Arm in which patients first randomised to receive SLT laser
|
At the first treatment, SLT treatment will be delivered to 360 degrees of trabecular meshwork.
At the first escalation of treatment, the superior 180 degrees will be retreated.
Twenty-five non-overlapping shots per quadrant will be used with a starting power of 0.8 mJ and increments of 0.1 mJ (titrated to avoid large bubbles) with standard other settings (400 nm spot size, 3 nanosecond duration) using a Latina single-mirror goniolens.
The IOP will be checked 1 hour post treatment and five days of guttae acular tds will be administered to the treatment eye following treatment.
After 2 treatments of SLT, the laser treated arm of the study will follow the same pathway as the medical treatment arm.
Other Names:
|
Active Comparator: Topical therapy
Arm in which patients first selected to receive drops (Prostagladin analogue as first-line)
|
Treatment will be initiated with latanoprost 0.005%.
At the first IOP check (1-2 months), if the IOP has not reached target IOP, a second line agent will be added (β-Blocker unless contraindicated).
If target IOP is still not reached, a third agent will be considered (topical carbonic anhydrase inhibitor).
Treatment may be switched, instead, at the discretion of the clinician if the reduction of IOP with an agent is deemed to be no different than the pre-treatment IOP.
Surgical therapy will be considered if target IOP is not met, or there is high IOP (>35 mmHg) or advanced damage at presentation.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of drops (and surgical interventions) needed to reach target IOP.
Time Frame: Change in IOP at 6 months, 12 months and 2 years (from baseline).
|
Change in IOP at 6 months, 12 months and 2 years (from baseline).
|
|
Percentage success
Time Frame: At 6 months, 12 months and 2 years
|
Proportion of patients in whom SLT (or mono medical therapy) alone achieved target IOP.
|
At 6 months, 12 months and 2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Correlation of angle pigment grade with IOP reduction from SLT
Time Frame: 6 months, 12 months, 2 years
|
6 months, 12 months, 2 years
|
Comparison of percentage success and number of drops in current study with the equivalent results of patients with POAG in the LiGHT study
Time Frame: 1 year and 2 years
|
1 year and 2 years
|
Number of progressing patients in each study arm (SLT or medical therapy) in terms of visual field loss and HRT.
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Marcelo T Nicoela, MD, Capital District Health Authority/Dalhousie University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LIP-SLT-2012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glaucoma
-
Imperial College Healthcare NHS TrustIRIDEX CorporationNot yet recruitingGlaucoma | Glaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma Secondary | Glaucoma Traumatic | Glaucoma Uveitic
-
Wills EyeIOP OphthalmicsTerminatedPrimary Open Angle Glaucoma | Neovascular Glaucoma | Uveitic Glaucoma | Pseudoexfoliation Glaucoma | Primary Angle Closure Glaucoma | Pigmentary Glaucoma | Traumatic GlaucomaUnited States
-
Centre hospitalier de l'Université de Montréal...CompletedGlaucoma | Glaucoma, Open-Angle | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma and Ocular Hypertension | Glaucoma, Uncompensated | Glaucoma SecondaryCanada
-
Pro Top & Mediking Company LimitedCompletedOpen Angle Glaucoma | Neovascular Glaucoma | Angle Closure Glaucoma | Uveitis Glaucoma | Young Age Glaucoma | High Risk PatientEstonia
-
Sanoculis LtdCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaIsrael
-
Bausch & Lomb IncorporatedNicOx Inc.CompletedPrimary Open Angle Glaucoma | Ocular Hypertension | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
Sensimed AGCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaFrance
-
Wills EyeOptovueCompletedPrimary Open-angle Glaucoma | Normal Tension Glaucoma | Glaucoma; DrugsUnited States
-
Ivantis, Inc.CompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
University of California, San FranciscoUniversity of Colorado, Denver; University of Maryland; Zhongshan Ophthalmic... and other collaboratorsCompletedPrimary Open Angle Glaucoma | Glaucoma | Neovascular Glaucoma | Secondary GlaucomaUnited States, China, India, Mexico
Clinical Trials on SLT Laser
-
Meir Medical CenterCompletedPrimary Open Angle GlaucomaIsrael
-
Western University, CanadaCompletedOcular Hypertension | Intraocular Pressure | Primary Open Angle Glaucoma of Both EyesCanada
-
Carl Zeiss Meditec AGActive, not recruitingPrimary Open-angle GlaucomaGermany
-
University of KentuckyTerminated
-
University of ZurichUnknownOcular Hypertension | GlaucomaSwitzerland
-
University Hospital, GenevaTerminatedGlaucoma and Ocular HypertensionSwitzerland
-
Sunnybrook Health Sciences CentreCompleted
-
Technische Universität DresdenCompleted
-
Temple UniversityCompletedOcular Hypertension | Glaucoma | Open Angle Glaucoma | Pigment Dispersion Syndrome | Glaucoma, Open Angle, Pseudo-exfoliativeUnited States
-
Belkin Laser Ltd.CompletedOpen Angle GlaucomaGeorgia